Serum Epiplakin Might Be a Potential Serodiagnostic Biomarker for Bladder Cancer

Tumor markers that can be detected at an early stage are needed. Here, we evaluated the epiplakin expression levels in sera from patients with bladder cancer (BC). Using a micro-dot blot array, we evaluated epiplakin expression levels in 60 patients with BC, 20 patients with stone disease, and 28 he...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 20; p. 5150
Main Authors Shimura, Soichiro, Matsumoto, Kazumasa, Shimizu, Yuriko, Mochizuki, Kohei, Shiono, Yutaka, Hirano, Shuhei, Koguchi, Dai, Ikeda, Masaomi, Sato, Yuichi, Iwamura, Masatsugu
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 14.10.2021
MDPI
Subjects
Antibodies
Biomarkers
Bladder cancer
Cancer
Cancer therapies
Cellular biology
Cytology
Disease
Hospitals
Immunohistochemistry
Invasiveness
Multivariate analysis
Patients
Proteins
Software
Tumor markers
Tumors
United States > US
Japan
Online AccessGet full text

Cover

More Information
Summary:Tumor markers that can be detected at an early stage are needed. Here, we evaluated the epiplakin expression levels in sera from patients with bladder cancer (BC). Using a micro-dot blot array, we evaluated epiplakin expression levels in 60 patients with BC, 20 patients with stone disease, and 28 healthy volunteers. The area under the curve (AUC) and best cut-off point were calculated using receiver-operating characteristic (ROC) analysis. Serum epiplakin levels were significantly higher in patients with BC than in those with stone disease (p = 0.0013) and in healthy volunteers (p < 0.0001). The AUC-ROC level for BC was 0.78 (95% confidence interval (CI) = 0.69–0.87). Using a cut-off point of 873, epiplakin expression levels exhibited 68.3% sensitivity and 79.2% specificity for BC. However, the serum epiplakin levels did not significantly differ by sex, age, pathological stage and grade, or urine cytology. We performed immunohistochemical staining using the same antibody on another cohort of 127 patients who underwent radical cystectomy. Univariate and multivariate analysis results showed no significant differences between epiplakin expression, clinicopathological findings, and patient prognoses. Our results showed that serum epiplakin might be a potential serodiagnostic biomarker in patients with BC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13205150